Nectar Lifescience Ltd

Nectar Lifescience Ltd

Next 500 2024
+ 10 More
+ 10 More
OVERVIEW
FINANCIALS

About

Nectar Lifesciences Limited (NLL) is known for manufacturing cephalosporin antibiotics and medicines. Its journey began as a small active pharmaceutical ingredients (API) producer and has now transformed into being one of the leading players in the anti-infective therapeutic area. Its major business revolves around the manufacturing of APIs, formulations, and empty hard gelatin capsules. With the support of 11 manufacturing facilities in Punjab and Himachal Pradesh, NLL is able to serve and save lives in more than 45 countries. As per Bio-Spectrum Asia Pacific in 2016, Nestar Lifesciences is among the top 40 forerunners in the biopharmaceutical industry in the Asia-Pacific region.

Incorporation Year: 1995
Headquarters: Chandigarh
Top Management: Saniv Goyal
Industry: Pharma

Featured In Fortune India Ranking

Fortune 500 India
#443(2020)
#412(2019)
#497(2014)
#487(2013)
#443(2020)#412(2019)#497(2014)#487(2013)
Ranking Trend Fortune 500 India
Next 500 India
#357(2024)#186(2023)#119(2022)#19(2019)#42(2018)#3(2017)#2(2016)
#357(2024)#186(2023)#119(2022)#19(2019)#42(2018)#3(2017)#2(2016)
Ranking Trend Fortune Next 500 India

Financial Data 2024

Revenue
1,739
(INR Cr)
Net Operating Income
1,684
(INR Cr)
Assets
1,713
(INR Cr)
Profit
5
(INR Cr)
Net Worth
1,069
(INR Cr)

Financial Data

RevenueNet Operating IncomeProfitAssetsNet Worth
PARAMETERS2024202320222021202020192018201720162015201420132012201120102009
Revenue
(INR Cr)
1739
8.1%
1608
-3.4%
1664
15.4%
1443
-39.3%
2375
-16.4%
2839
48.5%
1912
15.3%
1658
-2.8%
1706
0.8%
1692
-0.9%
1708
0.1%
1707
16.8%
1461
26.2%
1158
28.5%
901
3.7%
869
-
Net Operating Income
(INR Cr)
1684
10.53%
1524
-8.70%
1669
8.13%
1543
-34.78%
2366
-14.97%
2783
48.32%
1876
14.15%
1644
-1.91%
1676
1.95%
1644
0.33%
1638
0.74%
1626
23.85%
1313
23.64%
1062
25.57%
846
16.19%
728
-1.08%
Profit
(INR Cr)
5
-
-24
-
25
-
-73
-
32
-33.2%
48
-8.9%
52
-5.6%
55
2.0%
54
-18.1%
66
6.7%
62
-27.6%
86
17.1%
73
-29.7%
104
12.9%
92
74.2%
53
-
Assets
(INR Cr)
1713
-6.1%
1826
-6.7%
1956
-1.0%
1976
2.6%
1926
-5.2%
2031
-0.5%
2041
6.7%
1913
-1.4%
1940
1.9%
1904
6.3%
1791
2.3%
1752
-4.4%
1833
33.5%
1373
12.4%
1222
21.2%
1008
-
Net Worth
(INR Cr)
1069
0.4%
1065
-2.1%
1088
2.4%
1062
-6.5%
1136
2.8%
1105
4.4%
1059
5.2%
1007
5.5%
954
-0.4%
958
3.3%
927
6.9%
868
10.6%
784
8.8%
721
16.2%
621
104.6%
303
6.8%
Employee Cost
(INR Cr)
82
8.7%
75
4.5%
72
1.9%
71
-9.7%
78
2.2%
77
2.5%
75
-1.2%
76
-3.6%
78
33.0%
59
22.9%
48
5.1%
46
3.9%
44
30.0%
34
16.7%
29
11.0%
26
-
Interest Cost
(INR Cr)
877979112126148115117123126138115115746050
Cash & Bank Balance
(INR Cr)
201818262121913373310626333534
Total Debt
(INR Cr)
6367548609037799039558789629258588791043648601704

Key Financial Ratios

Profit As % Of RevenuesRONW %Interest Cost to EBITDA %ROCE %Debt to Equity Ratio
PARAMETERS2024202320222021202020192018201720162015201420132012201120102009
Profit As % Of Revenues 0.3%-1.5%-1.3%1.7%2.7%3.3%3.2%3.9%3.6%5.0%5.0%9.0%10.2%6.1%
Profit As % Of Assets 0.3%-1.3%-1.7%2.3%2.6%2.9%2.8%3.5%3.5%4.9%4.0%7.6%7.6%5.3%
Profit As % Of Networth 0.5%-2.3%-2.8%4.3%4.9%5.5%5.7%6.9%6.7%9.9%9.3%14.5%14.9%17.5%
Interest Cost to EBITDA % 57.5%150.0%49.7%133.8%57.3%56.1%48.8%52.3%51.7%47.1%47.8%39.8%46.4%32.6%30.9%36.0%
Debt to Equity Ratio 0.590.710.790.850.690.820.900.871.010.970.931.011.330.900.972.32
RONW 0.5%-1.7%-2.8%4.4%5.1%5.6%5.7%7.0%6.9%10.4%9.7%15.5%20.0%18.0%
ROCE 6.0%-0.2%5.3%2.7%8.3%10.2%9.0%9.6%9.7%11.4%12.2%12.9%12.5%15.0%15.8%12.8%